Zaher El-Assi joins Executive Management Team
PHILADELPHIA – August 20, 2018 – ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced the appointment of Zaher El-Assi as Executive Vice President and Product Line Executive for electronic Clinical Outcome Assessments (eCOA). In this role, he is responsible for defining and leading the product strategy for ERT’s eCOA solutions and services.
El-Assi brings more than two decades of global business acumen to ERT, including senior management roles in the clinical research, healthcare, and drug development industries. Previously, El-Assi was Vice President, Global Commercial Leader at Watson Health, a division of IBM, where he led global sales and innovation for the company’s Oncology and Life Sciences business unit as well as its Consumer Health and Ecosystems group.
“Zaher is an outstanding addition to ERT’s executive management team,” said James Corrigan, President and CEO of ERT. “Based on his extensive experience, he is well positioned to advance our global eCOA strategy and ensure that our solutions continue to meet our customers’ needs.”
“I’m delighted to join ERT at this pivotal time, when technological advances are helping clinical trial sponsors overcome many of their biggest development challenges.” said El-Assi. “ERT’s proven eCOA solutions help our customers to abandon traditional, error-prone paper methods and easily implement a modern, quality-driven approach to clinical trial data capture so they can improve clinical trial efficiencies and get new therapies to market faster.”
For more information on how ERT’s eCOA solution minimizes uncertainty and risk so clinical trial sponsors can move ahead quickly, visit ert.com/eCOA.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2017, ERT supported more than 60% of all FDA drug approvals. Pharma companies, biotechs and CROs have relied on ERT solutions in 13,000+ studies, spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.